THERAPEUTIC AREA
saveOphthalmology
Diseases of the eye and visual system.
also known as: eye, vision, ocular
🐶 often sniffed alongside
top 8- tagApproval176 co-mentions · 88 sources
- tagRecall128 co-mentions · 36 sources
- drugapraclonidine hydrochloride88 co-mentions · 44 sources
- tagAdCom60 co-mentions · 53 sources
- drugFlarex56 co-mentions · 28 sources
- company$CAHCARDINAL HEALTH INC38 co-mentions · 5 sources
- tag510(k) Clearance31 co-mentions · 26 sources
- tagPMA Approval29 co-mentions · 27 sources
drugs
368
catalysts
16
news
1,133
companies
258
Top drugs
view all →Marketed
Restasis
Keratoconjunctivitis Sicca (Dry Eye)
$ABBV · 123 catalysts
Marketedadalimumab
Intermediate Uveitis
$ABBV · 61 catalysts
MarketedDOXYCYCLINE HYCLATE
$AMRX · 49 catalysts
Marketedmethylprednisolone sodium succinate
Drug Hypersensitivity Reactions
48 catalysts
MarketedMETHYLPREDNISOLONE ACETATE
Giant Cell Arteritis (Temporal Arteritis/Cranial Arteriti…
41 catalysts
Marketedprednisolone acetate
Anterior Segment Inflammation
$ABBV · 37 catalysts
MarketedMEDROL
$PFE · 34 catalysts
MarketedMINOCYCLINE HYDROCHLORIDE
Actinomycosis
34 catalysts
🐶 Top companies
view all →Recent catalysts
view all →Apr 30, 2026
phase 2 completion
Shenzhen Eye Hospital — umbilical cord mesenchymal stem cells derived apoptotic vesicles (Phase II Trial Completion)
umbilical cord mesenchymal stem cells derived apoptotic vesicles
→
Apr 30, 2026
phase 1 2 completion
Eyebiotech Ltd — MK-8748 (Phase I/II Trial Completion)
MK-8748
→
Apr 30, 2026
phase 1 completion
Ilife Consulting Sarl — PST-611 (Phase I Trial Completion)
PST-611
→
Apr 30, 2026
filing
Xbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))
ranibizumab biosimilar
→
Apr 30, 2026
filing
Xbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))
ranibizumab biosimilar
→
Apr 30, 2026
filing
Xbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))
ranibizumab biosimilar
→
Apr 30, 2026
filing
Xbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))
ranibizumab biosimilar
→
Apr 30, 2026
filing
Xbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))
ranibizumab biosimilar
→
Apr 29, 2026
phase 3 initiation
All India Institute of Medical Sciences Bathinda — mitomycin (Phase III Trial Initiation)
Jelmyto
→
Apr 29, 2026
phase 2 completion
Massachusetts Eye and Ear Infirmary — N-acetylcysteine (Phase II Trial Completion)
N-acetylcysteine
→
Recent news
view all →- STAT+: 7 burning questions about the FDA’s post-Overton futurestat · 6h ago
- FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Diseasefda press · 7h ago
- GSK nabs FDA greenlight for second lung cancer asset from Nuvalent buybiospace · 13h ago
- Pfizer enters in vivo CAR-T space via 3-program, $2.6B deal with China’s Starnafiercebiotech · 17h ago
- At Fierce’s London event, Big Pharmas tell biotechs to ‘be transparent’ to secure dealsfiercebiotech · 23h ago
- FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwidefda press · 1d ago
- J&J bets $2.2B on Ollin’s vision loss drugbiopharma dive · 2d ago
- ALDI Recalls Priano Protein Carbonara Tortelloni and Priano Protein Herb & Cheese Tortelloni Because Of Possible Health Riskfda recalls · 2d ago
Data sources
last refreshed 2m ago
Found something off?
comments(0)
5-min edit window · permanent after that